[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100252744":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":30,"responsibleParty":52,"collaborators":17,"id":55,"slug":56,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":17,"eligibilityCriteria":61,"healthyVolunteers":57,"sex":62,"minAge":63,"maxAge":64,"enrollmentInfo":65,"targetDuration":17,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":76,"overallStatus":33,"whyStopped":17,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"Montana State University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Creatine monohydrate","EXPERIMENTAL","5 grams of daily creatine monohydrate by mouth for 8 weeks",[13],"Drug: Creatine monohydrate",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG",null,[9],[20],"Creapure",[22],{"name":23,"affiliation":5,"role":24},"Tracy Hellem, PhD","PRINCIPAL_INVESTIGATOR",[26],{"name":23,"role":27,"phone":28,"phoneExt":17,"email":29},"CONTACT","406 243 2110","tracy.hellem1@montana.edu",[31],{"facility":32,"status":33,"city":34,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"Montana State University College of Nursing (Missoula campus)","RECRUITING","Missoula","Montana","59812","United States","US",{"type":40,"coordinates":41},"Point",[42,43],-113.994,46.87215,{"lat":43,"lon":42},[46,49,51],{"name":23,"role":27,"phone":47,"phoneExt":17,"email":48},"406-243-2110","tracy.Hellem1@montana.edu",{"name":17,"role":27,"phone":50,"phoneExt":17,"email":17},"4062432110",{"name":23,"role":24,"phone":17,"phoneExt":17,"email":17},{"type":24,"investigatorFullName":53,"investigatorTitle":54,"investigatorAffiliation":5,"oldNameTitle":17,"oldOrganization":17},"Tracy Hellem","Assistant Professor","100252744","phase-3-creatine-for-depressed-male-and-female-methamphetamine-users-100252744",false,"NCT02568878","Creatine for Depressed Male and Female Methamphetamine Users","An Open-Label Pilot Study of Creatine for Depressed Male and Female Methamphetamine Users","Inclusion Criteria:\n\n* Current primary diagnosis of methamphetamine dependence or abuse, with methamphetamine preferred drug of abuse\n* Current diagnosis of major depressive disorder (primary or substance-induced)\n* Current diagnosis of an anxiety disorder (primary or substance-induced)\n* Current Hamilton Depression Rating scale score \\> or = to 16\n* Current Hamilton Anxiety Scale score \\> = to 18\n* If taking a psychotropic medication for depressed or anxious mood, regimen must be stable for \\> = to 4 weeks prior to creatine treatment initiation\n\nExclusion Criteria:\n\n* Persons unable to provide adequate informed consent\n* Persons who are at clinically significant suicidal or homicidal risk\n* Primary substance-related diagnosis other than methamphetamine dependence or abuse\n* Positive pregnancy test (females only)\n* History of renal disease\n* Clinically significant medical or neurological illness identified by history, physical exam and laboratory testing\n* History of hypersensitivity reaction to creatine","ALL","18 Years","59 Years",{"count":66,"type":67},29,"ESTIMATED","INTERVENTIONAL",[70],"PHASE3","* Assess the antidepressant\u002Fanxiolytic effect of creatine in male and female methamphetamine users\n* Assess creatine's effect on methamphetamine use\n* Assess the safety of creatine in male methamphetamine users with depression",[73,74,75],"Depression","Anxiety","Methamphetamine Dependence",[73,74,77],"Methamphetamine dependence","2015-12-10",{"date":80,"type":67},"2015-12-11",{"date":82,"type":17},"2015-11",{"date":84,"type":67},"2017-05",{"name":5,"class":6},1]